Zydus Lifesciences Ltd
Zydus Lifesciences Ltd (ZYDUSLIFE) last reported results for the quarter ended Jun 2026, with sales of ₹8,017 crore and net profit of ₹990 crore. Zydus Lifesciences Ltd’s board meets on 1 Dec 2026. The stock last traded at ₹1,158, a market capitalisation of ₹1,15,511 crore, on a P/E of 23.7. Over the past 52 weeks the stock has ranged between ₹836 and ₹1,232. Figures are as of 6 Oct 2026 and are not real time.
Zydus Lifesciences Ltd share price and key metrics
- Current price
- ₹1,158
- Market cap
- ₹1,15,511 cr
- Stock P/E
- 23.7
- Book value
- ₹269
- ROE
- 21.2%
- ROCE
- 21.1%
- Dividend yield
- 0.09%
- 52w high / low
- 1232/836
Metrics as of 6 Oct 2026. Not real time.
Track Zydus Lifesciences Ltd
Cruxal reads every Zydus Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Zydus Lifesciences Ltd growth and returns
- 10 Years
- 11%
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- 21%
- 10 Years
- 11%
- 5 Years
- 19%
- 3 Years
- 32%
- TTM
- 5%
- 10 Years
- 11%
- 5 Years
- 16%
- 3 Years
- 24%
- 1 Year
- 15%
- 10 Years
- 20%
- 5 Years
- 21%
- 3 Years
- 21%
- Last Year
- 21%
Zydus Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8,017 cr, up 22.0% from ₹6,574 cr a year earlier. Net profit was ₹990 cr, down 34.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 |
| Expenses | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 |
| Operating profit | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 |
| OPM % | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% |
| Other income | 68 | 57 | -139 | 155 | 75 | 26 | -263 | 88 |
| Interest | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 |
| Depreciation | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 |
| Profit before tax | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Tax % | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% |
| Net profit | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS (₹) | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.42 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Zydus Lifesciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9,376 | 11,905 | 13,166 | 14,253 | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 | 28,592 |
| Operating profit | 1,902 | 2,831 | 2,991 | 2,798 | 3,344 | 3,342 | 3,860 | 5,384 | 7,058 | 8,475 | 8,316 |
| OPM % | 20% | 24% | 23% | 20% | 22% | 22% | 22% | 28% | 30% | 31% | 29% |
| Net profit | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | 4,593 |
| EPS (₹) | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 | 50.09 | 44.94 |
TTM is the trailing twelve months to the most recent quarter.
Zydus Lifesciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 |
| Reserves | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,852 | 27,011 |
| Borrowings | 5,207 | 5,407 | 7,899 | 7,986 | 4,584 | 4,221 | 1,195 | 804 | 3,213 | 12,496 |
| Other liabilities | 2,937 | 3,632 | 4,945 | 5,115 | 6,189 | 6,421 | 6,851 | 8,201 | 9,523 | 11,065 |
| Total liabilities | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 50,673 |
| Fixed assets | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,253 | 11,521 | 12,368 | 13,134 | 24,106 |
| CWIP | 1,543 | 1,527 | 837 | 742 | 783 | 661 | 1,201 | 2,423 | 2,692 | 3,698 |
| Investments | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,220 | 6,412 | 7,540 |
| Other assets | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 12,822 | 14,451 | 15,328 |
| Total assets | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 36,689 | 50,673 |
As reported by the company. Total assets equal total liabilities by construction.
Zydus Lifesciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,312 | 919 | 1,282 | 2,505 | 3,293 | 2,104 | 2,689 | 3,228 | 6,781 | 2,117 |
| Cash from investing | -2,872 | -974 | -3,977 | -1,012 | -835 | 1,137 | 1,178 | -1,492 | -8,363 | -7,895 |
| Cash from financing | 2,316 | 52 | 1,885 | -1,094 | -2,549 | -868 | -4,400 | -1,810 | 1,995 | 5,807 |
| Net cash flow | 756 | -3 | -811 | 399 | -90 | 2,373 | -534 | -75 | 414 | 28 |
| Free cash flow | -1,623 | -116 | 236 | 1,617 | 2,446 | 1,050 | 1,697 | 2,345 | 5,139 | -530 |
| CFO / operating profit | 81% | 54% | 65% | 100% | 109% | 83% | 85% | 84% | 122% | 44% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Zydus Lifesciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 16% | 18% | 15% | 11% | 14% | 13% | 15% | 22% | 24% | 21% |
| Debtor days | 89 | 98 | 110 | 94 | 76 | 80 | 94 | 97 | 64 | 73 |
| Inventory days | 193 | 211 | 208 | 207 | 227 | 245 | 197 | 202 | 227 | 282 |
| Days payable | 165 | 167 | 149 | 151 | 155 | 141 | 123 | 125 | 131 | 142 |
| Cash conversion cycle | 116 | 142 | 169 | 150 | 148 | 184 | 168 | 175 | 160 | 212 |
| Working capital days | -34 | 17 | 10 | -19 | -6 | 19 | 70 | 88 | 3 | -40 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Zydus Lifesciences Ltd shareholding pattern
Promoters held 75.02% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.89% and DIIs 11.27%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.98% | 74.98% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.02% |
| FIIs | 7.52% | 7.53% | 7.31% | 7.13% | 7.34% | 7.06% | 6.95% | 6.89% |
| DIIs | 10.59% | 10.61% | 10.95% | 11.09% | 10.86% | 11.08% | 11.20% | 11.27% |
| Government | 0.05% | 0.05% | 0.05% | 0.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 6.85% | 6.85% | 6.69% | 6.74% | 6.81% | 6.86% | 6.86% | 6.83% |
| No. of shareholders | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 | 4,03,266 | 4,18,314 | 3,99,251 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Zydus Lifesciences Ltd’s board next meet?
Zydus Lifesciences Ltd’s board meets on 1 Dec 2026.
- Board meetingExtension of Share Subscription and Shareholders’ Agreement
See the full results calendar for every Indian company reporting in the next 30 days.
Zydus Lifesciences Ltd corporate filings
- Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.Company Updatelow impact
- Zydus Lifesciences partners with MSN to launch first generic of Adempas (Riociguat Tablets) in the U.S.Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences announced a partnership with MSN to launch the first generic version…
Read the full analysis - Zydus Lifesciences Extends Timeline for 50% Investment in Zydus Sunshine Lifesciences JV to December 2026Company Updatemedium impact
Cruxal's analysis: Zydus Lifesciences Limited has announced a delay in completing its planned 50% equity…
Read the full analysis - Zydus Lifesciences concludes USFDA inspection at Ahmedabad SEZ II manufacturing facilityCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has announced the conclusion of a USFDA inspection at its…
Read the full analysis - Intimation of Trading Window ClosureInsider Trading / SASTlow impact
- Zydus Lifesciences concludes USFDA inspection of pharmacovigilance system with nil observationsCompany Updatemedium impact
Cruxal's analysis: Zydus Lifesciences announced that the USFDA has concluded an inspection of its…
Read the full analysis - Zydus Lifesciences Limited issues notice regarding loss of share certificateCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences Limited has issued a formal notice regarding the loss of a share…
Read the full analysis - Zydus Lifesciences announces special window for physical securities transfer and dematerializationCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has published a notice in the Financial Express (English and Gujarati…
Read the full analysis - Zydus Lifesciences Limited Credit Ratings Reaffirmed at CRISIL AAA/Stable and A1+Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences Limited has received a reaffirmation of its credit ratings from CRISIL…
Read the full analysis - Zydus Lifesciences to participate in J.P. Morgan India Conference on September 21, 2026Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has announced its participation in the J.P. Morgan India Conference…
Read the full analysis - Zydus Lifesciences Limited issues notice regarding loss of share certificateCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences Limited has published a formal notice regarding the loss of a share…
Read the full analysis - Zydus Lifesciences Ltd announces settlement agreementCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has disclosed a settlement agreement. The filing provides no specific…
Read the full analysis - Zydus Lifesciences 31st AGM Transcript: Management Reaffirms Growth Strategy, Debt Reduction, and Innovation FocusAGM/EGMlow impact
Cruxal's analysis: Zydus Lifesciences Limited held its 31st Annual General Meeting on August 11, 2026, where…
Read the full analysis - Zydus Lifesciences Reports Positive Phase II(b) Clinical Trial Results for Saroglitazar Mg in MASHCompany Updatehigh impact
Cruxal's analysis: Zydus Lifesciences has announced successful topline results from its global EVIDENCES-X…
Read the full analysis - Zydus Lifesciences incorporates new wholly owned subsidiary in GIFT City, GujaratCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has incorporated a new wholly owned subsidiary in the Gujarat…
Read the full analysis - Zydus Lifesciences Ltd discloses ESG rating updateCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has provided a disclosure regarding its ESG rating. This is a routine…
Read the full analysis - Zydus Lifesciences Ltd: Routine disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Zydus Lifesciences has filed a routine disclosure in compliance with the SEBI…
Read the full analysis - Zydus Lifesciences Releases Investor Presentation Highlighting FY26 Financial Performance and Strategic Growth PillarsCompany Updatemedium impact
Cruxal's analysis: Zydus Lifesciences Limited has released its corporate presentation for an investor…
Read the full analysis - Zydus Lifesciences Ltd discloses ESG rating updateCompany Updatelow impact
Cruxal's analysis: Zydus Lifesciences has released an update regarding its ESG rating. The disclosure is a…
Read the full analysis - Zydus Lifesciences receives USFDA approval for Ascorbic Acid Injection with 180-day CGT exclusivityCompany Updatemedium impact
Cruxal's analysis: Zydus Lifesciences has secured final approval from the USFDA for Ascorbic Acid Injection…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.